Marinosomes System Development

Marinosomes are liposomes based on natural marine lipid extracts containing high ratios of polyunsaturated fatty acids such as eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). Marinosomes have the potential to be developed as targeted drug delivery systems for a wide range of applications in pharmaceuticals, nutritional supplements, etc. They are not present in the normal skin epidermis.

Background of the Marinosomes Drug Delivery System

The marinosomes drug delivery system is actually a vesicular system with an overall structure of spherical phospholipid vesicles with phosphatidylcholine and phosphatidylethanolamine as the main components. The marine lipid-based vesicle structure has an aqueous core surrounded by a hydrophobic lipid bilayer that allows the marinosomes to carry both hydrophilic and hydrophobic drugs, through which hydrophobic compounds are inserted into the bilayer and hydrophilic compounds are trapped in the aqueous center. In addition, the large hydrophilic core and biocompatible lipid layer allow the marinosome to deliver a number of large molecules. Marinosomes deliver drugs to specific sites of action by fusing the lipid bilayer to other lipid membrane structures and then releasing the contents.

Marinosomes System Development

As a specialized biological company, CD Formulation has built a complete lipid drug delivery platform for our customers to better serve researchers worldwide. We are pleased to provide high-quality marinosomes system development services to our clients around the world.

Evaluation of Marinosomes

• Optical Density Evaluation

Turbidity measurements can be performed using a spectrophotometer in a thermostated cellular scaffold at 37°C to track the stability of marinosomes as a function of time.

• Surface charge evaluation

The zeta potential of marinosomes was measured using a zeta meter. The zeta potential (mV) of marinosomes was determined by electrophoretic mobility at a phospholipid concentration of 6 mg/mL.

• Particle size evaluation

Particle size distributions, i.e. mean diameter and polydispersity index, were determined by quasi-elastic light scattering (QELS) and particle size measurements. For each sample, data are collected, typically lasting 10 minutes, in three runs over an angular range of 30 to 150°C. Size measurements were also performed using a photon correlation spectrophotometer.

• Drug release evaluation

Drugs are released by diffusing cells in vitro, which in turn allows for pharmacokinetic and drug effect analysis of drug-loaded Marinosomes.

Marinosomes for Drug Transport Applications

• Role in enzyme delivery

Marinosomes can be used to deliver enzymes such as streptokinase, proteases. marinosome coated enzymes can be used to treat a variety of enzyme deficiency diseases, such as albinism caused by tyrosinase deficiency due to homogeneous acid oxidase deficiency.

• Marine proteasomes for vitamin delivery

Marinosomes can act as delivery systems for lipid and water-soluble compounds and appear to be potential candidates for worker feeds, such as fat-soluble vitamins, such as vitamin E.

• Marinosome as a vaccine carrier

Studies on cardiolipin revealed the importance of bilayer structures in antiserum production and concluded that liposomes are actually responsible for the antigenicity of these lipids (e.g. naturally occurring lipids) and therefore marinosomes also have an auxiliary role for protein antigens.

Advantages of the Marinosomes System

• Compared to liposomes, marinosomes are stable over a wide range of pH and high temperatures.
• Marine phospholipids are considered as an attractive liposomal material for oral polyunsaturated fatty acid supplementation due to their high lipid bioavailability.
• Marinosomes increase the circulating life of the drug and allow easy deposition of the drug in the tissues.
• Marinosomes protect the metabolic degradation of drugs.
• Marinosomes alter the tissue distribution of drugs, enhancing drug uptake by mononuclear phagocyte-rich organs in the liver, spleen, and bone marrow, and decreasing drug uptake by the kidneys, heart muscle, and brain.